◆ 会议时间：2024年9月11-15日
◆ 会议地点：美国 芝加哥
◆ 会议简介：
2024年国际乙型肝炎病毒(HBV)会议将于2024年9月11-15日在美国芝加哥举行。
国际乙型肝炎病毒（HBV）分子生物学会议是由Jesse Summers博士和Harold Varmus博士于1985年在纽约发起举办，是国际上专注于乙肝病毒（HBV）和丁型肝炎病毒（HDV）的权威科学会议，目的是汇集研究乙肝和丁肝病毒、相关动物模型病毒及乙型肝炎诱导肝细胞癌方面的国际科学家，为初级和高级科学家宣提供广泛的机会，共同讨论关于这些病毒病原体和相关疾病的最新概念和技术进展。大会主题包括生物化学、分子生物学、传统病毒学、免疫学、发病机理和致癌作用，以及针对这两种病毒的抗病毒治疗的最新进展。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.
2024 International HBV Meeting
时间/Date:
September 11-15, 2024
地点/Venue:
Chicago, USA
摘要征文投稿：
Abstract Submission
General Abstracts
- All abstracts must be submitted by 3 p.m. EDT on June 20, 2024, to be considered for presentation at the HBV Meeting. Presentation notifications will be sent in timeline to be announced.
- Click on the button below to access the Abstract Submission Portal; going live in February 2024.
点此提交摘要>>>Submit Abstract>>>
Abstracts will be submitted to the following session topics.
- Molecular Virology
- Immunology/Pathogenesis
- Therapy
Abstracts that are selected for presentations will be allocated to a session by the meeting organizers.
- The presenting author MUST be registered for the meeting in order for an abstract to be included in the program book.
- Oral and Poster Presentation Guidelines will be shared as the meeting approaches.
Details about abstract submissions:
- Titles should use "sentence caps" style, i.e., only capitalize the first word in the title and use lowercase for remainder of title (except if the scientific word requires caps such as 'HBV' or 'DNA,' etc.).
- Abstracts must be 300 words or less.
- We encourage attendees to submit abstracts that have not yet been published. Those that have been published elsewhere and do not have significant new information will get low priority to be selected for an oral presentation.
Important dates to note:
- June 20, 2024, will be the last day to submit abstracts and travel grants.
- Late July is when presentation and travel grant recipients will be notified.
- Late July will be the presentation and travel grant acceptance deadline.
Important Reminder:
- All travel grant requests must be submitted by 3 p.m. EDT on June 20, 2024.
注册费：
Early bird registration will end 7/20/24.
Late registration will close 8/18/24.
Final payment due on 8/23/24.
An Early Career Scientist is a scientist/researcher with 5-6 years post-doctorate experience or less, who does not work independently and is not the "Principal Investigator" on grants.
Regular Members are scientists and researchers working for a non-profit organization such as a hospital, university lab, or research facility.
Industry/Pharmaceutical Members are those who work in for-profit businesses such as providers of medical services and products, biotechnology companies, pharmaceutical companies, and companies who offer services and products to academic and research companies and institutions.
Retired Fellow: Retaining access to the deep understanding of HBV and institutional knowledge possessed by retired HBV researchers is beneficial to the HBV research community and attendees at the International HBV Meeting. To encourage continued attendance at the HBV Meeting by retirees, registration fees will be waived for retired HBV researchers who spent the majority of their careers in academia. This waiver does not include expenses for travel, housing or the end-of-meeting banquet when the banquet fee is not bundled into the registration fee. Support for those expenses is at the discretion of the annual meeting organizers, with the understanding that the retirees receiving expanded financial support should have a formal role in the meeting, such as giving a keynote presentation. Researchers who spent the majority of their careers in industry are not eligible for this waiver. The Hepatitis B Foundation will notify the chairperson of the Scientific Advisory Council (SAC) when attendees register under the fee waiver option. Questions regarding eligibility for the fee waiver will be resolved by the SAC, and the SAC chairperson is authorized to act on behalf of the SAC for minor matters.
◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|
